Cysticercosis

Summary

Cysticercosis (MONDO:0015484) is a disease and 7 clinical trials. Top therapeutic interventions include phenytoin, albendazole, and dexamethasone. A subtype of taeniasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 49
• Clinical trials: 7

Clinical features

Signs & symptoms

Clinical features (HPO)

49 HPO clinical features (Orphanet curated; top 49 by frequency):

HPO ID	Term	Frequency
HP:0000707	Abnormality of the nervous system	Very frequent (80-99%)
HP:0001250	Seizure	Frequent (30-79%)
HP:0002514	Cerebral calcification	Frequent (30-79%)
HP:0002922	Increased CSF protein concentration	Frequent (30-79%)
HP:0003474	Somatic sensory dysfunction	Frequent (30-79%)
HP:0004302	Functional motor deficit	Frequent (30-79%)
HP:0010576	Intracranial cystic lesion	Frequent (30-79%)
HP:0010651	Abnormal meningeal morphology	Frequent (30-79%)
HP:0010702	Increased circulating antibody level	Frequent (30-79%)
HP:0011805	Abnormal skeletal muscle morphology	Frequent (30-79%)
HP:0012443	Abnormality of brain morphology	Frequent (30-79%)
HP:0012703	Abnormal subarachnoid space morphology	Frequent (30-79%)
HP:0100702	Arachnoid cyst	Frequent (30-79%)
HP:0200149	CSF lymphocytic pleiocytosis	Frequent (30-79%)
HP:0410234	Increased anti-parasite IgE antibody level	Frequent (30-79%)
HP:0000651	Diplopia	Occasional (5-29%)
HP:0000708	Atypical behavior	Occasional (5-29%)
HP:0000712	Emotional lability	Occasional (5-29%)
HP:0000738	Hallucinations	Occasional (5-29%)
HP:0000925	Abnormality of the vertebral column	Occasional (5-29%)
HP:0000929	Abnormal skull morphology	Occasional (5-29%)
HP:0000933	Posterior fossa cyst at the fourth ventricle	Occasional (5-29%)
HP:0001637	Abnormal myocardium morphology	Occasional (5-29%)
HP:0002133	Status epilepticus	Occasional (5-29%)
HP:0002197	Generalized-onset seizure	Occasional (5-29%)
HP:0002354	Memory impairment	Occasional (5-29%)
HP:0002493	Upper motor neuron dysfunction	Occasional (5-29%)
HP:0002516	Increased intracranial pressure	Occasional (5-29%)
HP:0006824	Cranial nerve paralysis	Occasional (5-29%)
HP:0007359	Focal-onset seizure	Occasional (5-29%)
HP:0009745	Spinalarachnoid cyst	Occasional (5-29%)
HP:0012372	Abnormal eye morphology	Occasional (5-29%)
HP:0025258	Stiff neck	Occasional (5-29%)
HP:0100249	Calcification of muscles	Occasional (5-29%)
HP:0100561	Spinal cord lesion	Occasional (5-29%)
HP:0000541	Retinal detachment	Very rare (<1-4%)
HP:0000726	Dementia	Very rare (<1-4%)
HP:0000741	Apathy	Very rare (<1-4%)
HP:0001094	Iridocyclitis	Very rare (<1-4%)
HP:0001251	Ataxia	Very rare (<1-4%)
HP:0001260	Dysarthria	Very rare (<1-4%)
HP:0001268	Mental deterioration	Very rare (<1-4%)
HP:0001289	Confusion	Very rare (<1-4%)
HP:0001297	Stroke	Very rare (<1-4%)
HP:0002383	Infectious encephalitis	Very rare (<1-4%)
HP:0004420	Arterial thrombosis	Very rare (<1-4%)
HP:0007185	Loss of consciousness	Very rare (<1-4%)
HP:0012424	Chorioretinitis	Very rare (<1-4%)
HP:0025163	Abnormality of optic chiasm morphology	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	cysticercosis
Mondo ID	MONDO:0015484
EFO	EFO:0007231
MeSH	D003551
Orphanet	1560
DOID	DOID:10079
ICD-10-CM	B69
ICD-11	1324863907
NCIT	C34520
SNOMED CT	59051007
UMLS	C0010678
MedGen	4122
GARD	0008194
MedDRA	10011775
NORD	1027
Is cancer (heuristic)	no

Also known as: tapeworm infection: [intestinal taenia solium] or [pork] · tapeworm infection: intestinal taenia solum · tapeworm infection: pork

Disease family

This is a subtype of taeniasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › intestinal helminthiasis › taeniasis › cysticercosis

Related subtypes (1): coenurosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Albendazole	Approved (phase 4)
Dexamethasone	Phase 3 (in late-stage trials)
Omeprazole	Phase 3 (in late-stage trials)
Praziquantel	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetazolamide.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001205	Not specified	RECRUITING	Natural History of Treated Neurocysticercosis and Long-Term Outcomes
NCT00001912	Not specified	COMPLETED	Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
NCT00004403	Not specified	COMPLETED	Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
NCT01368354	Not specified	COMPLETED	Taenia Solium Control Case Study in Zambia
NCT03095339	Not specified	COMPLETED	EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso
NCT03808597	Not specified	COMPLETED	Digital Health Promotion in Iringa, Tanzania
NCT05010811	Not specified	COMPLETED	Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PHENYTOIN	4	2
ALBENDAZOLE	4	1
DEXAMETHASONE	4	1